HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuichiro Ohe Selected Research

amrubicin

11/2019Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
1/2017Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
1/2017Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
9/2016Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
10/2015Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
4/2014Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
4/2014A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
12/2012Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
4/2012Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
9/2010Severe interstitial lung disease associated with amrubicin treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuichiro Ohe Research Topics

Disease

155Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 02/2002
114Neoplasms (Cancer)
07/2022 - 01/2002
44Lung Neoplasms (Lung Cancer)
12/2022 - 05/2002
23Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2021 - 05/2002
18Interstitial Lung Diseases (Interstitial Lung Disease)
07/2022 - 07/2004
17Neutropenia
12/2020 - 02/2005
16Disease Progression
05/2022 - 07/2006
13Adenocarcinoma of Lung
01/2021 - 02/2007
12Neoplasm Metastasis (Metastasis)
01/2021 - 05/2007
11Diarrhea
06/2022 - 05/2007
9Carcinoma (Carcinomatosis)
01/2022 - 08/2005
9Adenocarcinoma
10/2020 - 05/2002
8Thymoma (Thymic Carcinoma)
10/2020 - 05/2015
7Febrile Neutropenia
12/2020 - 10/2015
6Exanthema (Rash)
01/2022 - 09/2009
5Malignant Mesothelioma
06/2021 - 06/2019
5Radiation Pneumonitis
01/2021 - 07/2006
5Drug-Related Side Effects and Adverse Reactions
08/2020 - 03/2007
5Thrombocytopenia (Thrombopenia)
01/2020 - 12/2009
4Pneumonia (Pneumonitis)
10/2022 - 01/2012
4Anemia
01/2020 - 08/2006
3Lymphoma (Lymphomas)
01/2022 - 10/2006
3Nausea
04/2021 - 10/2018
3Vomiting
04/2021 - 10/2018
3Infections
01/2021 - 07/2012
3Fever (Fevers)
12/2020 - 02/2004
3Ovarian Neoplasms (Ovarian Cancer)
12/2020 - 06/2010
3Fatigue
10/2020 - 10/2006
3Lung Injury
11/2019 - 07/2006
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2015 - 12/2009
2Stomatitis
06/2022 - 05/2022
2Cachexia
02/2022 - 01/2014
2Dermatitis
05/2021 - 06/2016

Drug/Important Bio-Agent (IBA)

40ErbB Receptors (EGF Receptor)IBA
01/2022 - 10/2005
37Cisplatin (Platino)FDA LinkGeneric
04/2022 - 02/2002
30Tyrosine Kinase InhibitorsIBA
02/2022 - 10/2006
27PlatinumIBA
04/2022 - 05/2002
27NivolumabIBA
01/2022 - 01/2016
26Gefitinib (Iressa)FDA Link
04/2019 - 05/2002
21Pharmaceutical PreparationsIBA
07/2022 - 01/2002
19Carboplatin (JM8)FDA LinkGeneric
04/2021 - 01/2008
19Paclitaxel (Taxol)FDA LinkGeneric
01/2017 - 12/2003
18osimertinibIBA
06/2022 - 04/2015
16Irinotecan (Camptosar)FDA LinkGeneric
12/2020 - 01/2002
13pembrolizumabIBA
10/2022 - 01/2017
12B7-H1 AntigenIBA
03/2022 - 05/2015
12Docetaxel (Taxotere)FDA Link
01/2020 - 02/2002
11Immune Checkpoint InhibitorsIBA
03/2022 - 01/2016
11Biomarkers (Surrogate Marker)IBA
11/2021 - 01/2011
10amrubicinIBA
11/2019 - 09/2010
10Erlotinib Hydrochloride (CP 358,774)FDA Link
04/2019 - 10/2005
9alectinibIBA
05/2022 - 06/2013
9LigandsIBA
01/2022 - 05/2015
8Alanine Transaminase (SGPT)IBA
06/2022 - 12/2003
8Etoposide (VP 16)FDA LinkGeneric
12/2020 - 05/2002
7Monoclonal AntibodiesIBA
06/2021 - 01/2016
7CrizotinibIBA
07/2019 - 06/2013
6durvalumabIBA
04/2022 - 01/2020
6Pemetrexed (MTA)FDA Link
01/2020 - 07/2008
5Aspartate Aminotransferases (Aspartate Transaminase)IBA
06/2022 - 01/2019
5GemcitabineFDA Link
04/2021 - 02/2002
5Proteins (Proteins, Gene)FDA Link
10/2020 - 02/2007
5Anaplastic Lymphoma KinaseIBA
01/2020 - 02/2016
4Antineoplastic Agents (Antineoplastics)IBA
07/2022 - 08/2006
4Cytochrome P-450 CYP3AIBA
04/2022 - 02/2005
4AntiemeticsIBA
04/2022 - 10/2018
4Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022 - 07/2006
4Bevacizumab (Avastin)FDA Link
10/2019 - 12/2016
4DNA (Deoxyribonucleic Acid)IBA
01/2018 - 01/2012
4Biological ProductsIBA
01/2013 - 09/2007
3Aprepitant (Emend)FDA Link
04/2022 - 01/2020
3Dexamethasone (Maxidex)FDA LinkGeneric
04/2022 - 02/2016
3CytokinesIBA
02/2022 - 01/2002
3SteroidsIBA
05/2021 - 07/2006
3130-nm albumin-bound paclitaxelIBA
04/2021 - 06/2012
3AntibodiesIBA
01/2021 - 12/2015
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2020 - 04/2002
3Olanzapine (Zyprexa)FDA Link
01/2020 - 08/2016
3amrubicinolIBA
11/2019 - 04/2012
3Cadherins (E-Cadherin)IBA
08/2015 - 06/2012
3Vinorelbine (Navelbine)FDA LinkGeneric
02/2012 - 08/2004
3Hemoglobins (Hemoglobin)IBA
06/2010 - 08/2006
2AZD 6244IBA
06/2022 - 05/2022
2selpercatinibIBA
06/2022 - 01/2020
2EnzymesIBA
04/2022 - 02/2005
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2022 - 01/2002
2IpilimumabIBA
01/2022 - 01/2022
2Investigational DrugsIBA
04/2021 - 03/2016
2C-Reactive ProteinIBA
04/2021 - 12/2020

Therapy/Procedure

74Therapeutics
12/2022 - 07/2004
67Drug Therapy (Chemotherapy)
04/2022 - 02/2002
29Radiotherapy
01/2022 - 07/2004
25Chemoradiotherapy
04/2022 - 08/2003
6Combination Drug Therapy (Combination Chemotherapy)
01/2022 - 12/2004
6Immunotherapy
11/2021 - 05/2015
3Molecular Targeted Therapy
01/2022 - 12/2015
3Aftercare (After-Treatment)
01/2021 - 12/2013
3Adjuvant Chemotherapy
12/2020 - 05/2016
2Palliative Care (Palliative Therapy)
04/2022 - 11/2020
2Activities of Daily Living (ADL)
04/2021 - 06/2017